Cromwell Holdings LLC Buys 36 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Cromwell Holdings LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 830 shares of the pharmaceutical company’s stock after purchasing an additional 36 shares during the quarter. Cromwell Holdings LLC’s holdings in Vertex Pharmaceuticals were worth $386,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brookstone Capital Management boosted its stake in shares of Vertex Pharmaceuticals by 11.1% during the first quarter. Brookstone Capital Management now owns 2,368 shares of the pharmaceutical company’s stock valued at $990,000 after purchasing an additional 237 shares in the last quarter. Future Financial Wealth Managment LLC bought a new stake in Vertex Pharmaceuticals during the 1st quarter valued at $42,000. Wealthcare Advisory Partners LLC increased its holdings in shares of Vertex Pharmaceuticals by 4.6% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,218 shares of the pharmaceutical company’s stock valued at $1,345,000 after acquiring an additional 141 shares during the period. 180 Wealth Advisors LLC raised its position in shares of Vertex Pharmaceuticals by 42.9% in the 1st quarter. 180 Wealth Advisors LLC now owns 976 shares of the pharmaceutical company’s stock worth $408,000 after acquiring an additional 293 shares in the last quarter. Finally, Kathmere Capital Management LLC lifted its position in shares of Vertex Pharmaceuticals by 9.9% during the first quarter. Kathmere Capital Management LLC now owns 577 shares of the pharmaceutical company’s stock valued at $241,000 after buying an additional 52 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $477.70 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. Vertex Pharmaceuticals Incorporated has a 1 year low of $341.90 and a 1 year high of $510.64. The firm has a market capitalization of $123.27 billion, a PE ratio of 31.00 and a beta of 0.40. The business’s 50 day moving average price is $475.60 and its 200-day moving average price is $461.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The business had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period last year, the firm earned $3.53 EPS. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -2.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the topic of a number of analyst reports. TD Cowen lifted their price objective on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Canaccord Genuity Group boosted their target price on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the stock a “sell” rating in a research report on Wednesday, July 31st. Morgan Stanley raised their price target on shares of Vertex Pharmaceuticals from $462.00 to $474.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 1st. Piper Sandler boosted their price objective on shares of Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Royal Bank of Canada reduced their target price on Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $492.92.

Insider Activity at Vertex Pharmaceuticals

In other news, Director Sangeeta N. Bhatia sold 646 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the transaction, the director now directly owns 4,435 shares in the company, valued at $2,217,500. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Sangeeta N. Bhatia sold 646 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,005 shares of company stock valued at $5,988,066. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.